Balancing mitochondrial dynamics via increasing mitochondrial fusion attenuates infarct size and left ventricular dysfunction in rats with cardiac ischemia/reperfusion injury.
Animals
Apoptosis
/ drug effects
Cardiotonic Agents
/ administration & dosage
Humans
Male
Mitochondria, Heart
/ drug effects
Mitochondrial Dynamics
/ drug effects
Mitochondrial Proteins
/ metabolism
Myocardial Infarction
/ drug therapy
Myocardial Reperfusion Injury
/ drug therapy
Rats
Rats, Wistar
Ventricular Dysfunction, Left
/ drug therapy
Acute myocardial infarction
Heart
Ischemia-reperfusion injury
Mitochondrial dynamics
Mitochondrial fusion
Journal
Clinical science (London, England : 1979)
ISSN: 1470-8736
Titre abrégé: Clin Sci (Lond)
Pays: England
ID NLM: 7905731
Informations de publication
Date de publication:
14 02 2019
14 02 2019
Historique:
received:
06
01
2019
revised:
30
01
2019
accepted:
30
01
2019
pubmed:
2
2
2019
medline:
26
11
2019
entrez:
2
2
2019
Statut:
epublish
Résumé
An uncontrolled balance of mitochondrial dynamics has been shown to contribute to cardiac dysfunction during ischemia/reperfusion (I/R) injury. Although inhibition of mitochondrial fission could ameliorate cardiac dysfunction, modulation of mitochondrial fusion by giving a fusion promoter at different time-points during cardiac I/R injury has never been investigated. We hypothesized that giving of a mitochondrial fusion promoter at different time-points exerts cardioprotection with different levels of efficacy in rats with cardiac I/R injury. Forty male Wistar rats were subjected to a 30-min ischemia by coronary occlusion, followed by a 120-min reperfusion. The rats were then randomly divided into control and three treated groups: pre-ischemia, during-ischemia, and onset of reperfusion. A pharmacological mitochondrial fusion promoter-M1 (2 mg/kg) was used for intervention. Reduced mitochondrial fusion protein was observed after cardiac I/R injury. M1 administered prior to ischemia exerted the highest level of cardioprotection by improving both cardiac mitochondrial function and dynamics regulation, attenuating incidence of arrhythmia, reducing infarct size and cardiac apoptosis, which led to the preservation of cardiac function and decreased mortality. M1 given during ischemia and on the onset of reperfusion also exerted cardioprotection, but with a lower efficacy than when given at the pre-ischemia time-point. Attenuating a reduction in mitochondrial fusion proteins during myocardial ischemia and at the onset of reperfusion exerted cardioprotection by attenuating mitochondrial dysfunction and dynamic imbalance, thus reducing infarct size and improving cardiac function. These findings indicate that it could be a promising intervention with the potential to afford cardioprotection in the clinical setting of acute myocardial infarction.
Identifiants
pubmed: 30705107
pii: CS20190014
doi: 10.1042/CS20190014
doi:
Substances chimiques
Cardiotonic Agents
0
Mitochondrial Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
497-513Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.